Frank Li, CEO Stately Bio forecasting biological outcomes

Failed to add items

Sorry, we are unable to add the item because your shopping basket is already at capacity.

Please try again later

Please try again later

Please try again later

Listen for free

View show details

(2:10) Frank's background – Stanford, Palantir, Google, Calico, now Stately Bio

(4:35) What Stately Bio does – Marrying brightfield imaging with modern ML for live cell analysis

(8:10) Why brightfield imaging matters – Cheap, live, centuries-old tech meets new machine learning

(12:05) Real-time monitoring and forecasting biological outcomes

(18:20) How living cell observation shrinks iteration cycles

(24:45) Applications to stem cell therapies: diabetes, Parkinson’s, liver, heart, kidney

(30:10) ML advantage – Machine vision finds subtle signals invisible to humans

(35:50) Stately Bio’s early success – New York Blood Center partnership

(40:25) The cost advantage of imaging vs. single-cell omics

(44:30) Platform vs pipeline – Why Stately is building therapies, not just a tool

(50:00) Future verticals: Biomanufacturing, synthetic biology applications

(54:50) Frank’s journey – From coder to founder to biotech CEO

(1:00:05) Challenges in filtering conflicting advice as a founder

(1:04:40) Surprise learnings from scaling Stately

(1:09:00) ISCT conference announcements – New breakthroughs in suspension cells imaging

(1:13:25) Big vision – Starting the phenomics revolution through live-cell analysis

No reviews yet